INNAVIRVAX
InnaVirVax is a privately-owned biopharmaceutical company dedicated to the development of a cutting edge discovery in the field of therapy/prevention and prognostic of AIDS and HIV infection, other infectious diseases, and new cancer therapies.
INNAVIRVAX
Social Links:
Industry:
Biotechnology Health Diagnostics Therapeutics
Founded:
2008-01-01
Address:
Évry, Ile-de-France, France
Country:
France
Website Url:
http://www.innavirvax.fr
Total Employee:
11+
Status:
Active
Contact:
33 1 80 85 60 83
Email Addresses:
[email protected]
Total Funding:
12.17 M USD
Technology used in webpage:
Domain Not Resolving
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
BiOnSil
BiOnSil developing diagnostic and theranostic kits for the diagnosis of drug resistance in colorectal cancer.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
ValiPharma
ValiPharma develops therapeutics and diagnostics based on epigenomics for the detection and treatment of cancer.
Current Employees Featured
Founder
Investors List
Karista
Karista investment in Series A - InnaVirVax
Official Site Inspections
http://www.innavirvax.fr
- Host name: 104.247.81.52
- IP address: 104.247.81.52
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto
More informations about "InnaVirVax"
Santé : la PME francilienne InnaVirVax est le chef de file ... - Bpifrance
La PME chef de file de ce projet est InnaVirVax, société de biotechnologies localisée au Genopole® d’Evry (91) qui a développé une plateforme vaccinale dédiée à différentes …See details»
PRE-IPO INNAVIRVAX - Societe.com
Dec 3, 2020 PRE-IPO INNAVIRVAX, société par actions simplifiée, au capital social de 409667,00 EURO, dont le siège social est situé au 36 RUE DE MONCEAU, 75008 PARIS, …See details»
Minka-Tx | LinkedIn
Minka-Tx | 79 followers on LinkedIn. Following several months of strategic review and heavy financial restructuring, Innavirvax is reborn as Minka Therapeutics with a new sense of …See details»
Organization | InnaVirVax
InnaVirVax Report issue. For profit Phase 2. Founded: Very France (2008 ... Organization Overview. First Clinical Trial. 2012 NCT01549119. First Marketed Drug. None First NDA …See details»
InnaVirVax SA | Insights
Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
InnaVirVax S.A. - BioCentury Company Profiles - BCIQ
Aug 10, 2015 InnaVirVax S.A. - BioCentury Company Profiles for the biopharma industrySee details»
InnaVirVax Asset Profile | Preqin
InnaVirVax is based in France and operates as a biopharmaceutical company. Current Investors Karista, FaDiese, Fonds régional de co-investissement Île-de-FranceSee details»
InnaVirVax progresse contre le sida avec son immunothérapie
Sep 10, 2015 C'est le troisième tour de table pour InnaVirVax. Basée à Evry, la société de biotechnologies, spécialisée dans l'immunothérapie du sida, a levé cet été 3,6 millions d'euros …See details»
InnaVirVax Initiates Phase 2 Clinical Trial Evaluating VAC-3S, A ...
Dec 1, 2013 For more information, visit our newly launched website: www.innavirvax.fr . Contacts: In France for InnaVirVax: Milestones Press Relations Bruno ARABIAN Tel.: +33 1 …See details»
InnaVirVax va tester l'efficacité de son vaccin antisida
Jan 31, 2014 C'est le tout début de l'étude clinique de phase II de ce candidat vaccin antisida mis au point par InnaVirVax, qui va se dérouler sur plus de deux ans et inclure 90 malades …See details»
InnaVirVax C Funding Round - LinkedIn
Jul 6, 2015 I am pleased to announce that InnaVirVax has completed its third funding round of $4 million from its historical investors (FCPR CapDecisif 2, G1J Ile‐de‐France, Pradeyrol …See details»
InnaVirVax Takes In €3.6M Funding - PitchBook
InnaVirVax, a biopharmaceutical company developing therapies for infectious and major chronic diseases, has completed a €3.6 million financing.Investors include FCPR CapDecisif 2, G1J …See details»
Research programme: cancer and HIV biotherapies - InnaVirVax
InnaVirVax, a French privately-owned biopharmaceutical company, is developing biotherapies for the treatment of cancer and HIV infections. The cancer biotherapySee details»
HIV therapeutic vaccine enhances non-exhausted CD4 - Nature
Jun 3, 2019 Minka Therapeutics (InnaVirVax) as sponsor has been responsible for the study design, monitoring, data management, ad hoc primary statistical analyses, interpretation, and …See details»
InnaVirVax is making progresses against AIDS - LinkedIn
Sep 14, 2015 The first daily French financial newspaper, les Echos, commented on the development of InnaVirVax in an article entitled “InnaVirVax is making progresses against …See details»
VIH : phase I/IIa pour le candidat vaccin VAC-3S
InnaVirVax annonce de bons résultats précliniques avec son vaccin thérapeutique VAC-3S qui vise à combattre la pathogénicité du virus en bloquant la perte des lymphocytes CD4. Cette …See details»
Un essai d’immunothérapie anti-VIH à Paris - Le Quotidien du …
La société biopharmaceutique InnaVirVax (spécialisée dans la recherche et le développement de solutions thérapeutiques et diagnostiques pour les pathologies liées à des dérégulations …See details»
InnaVirVax lance un essai contre le VIH à l’AP-HP
LA SOCIÉTÉ biopharmaceutique InnaVirVax annonce le lancement d’un essai de phase I/IIa pour évaluer un nouveau traitement dans l’infection à VIH, le VAC-3S. L’étude est réalisée dans …See details»
InnaVirvax - Company Profile - Tracxn
Nov 16, 2024 InnaVirvax ranks 178th among 362 active competitors. 111 of its competitors are funded while 80 have exited. Overall, InnaVirvax and its competitors have raised over $11.4B …See details»